Mupirocin
Ointments
Isoleucine-tRNA Ligase
Staphylococcus aureus
Administration, Topical
Methicillin Resistance
Fusidic Acid
Drug Resistance, Bacterial
Chlorhexidine
Antibiotic Prophylaxis
Staphylococcal Skin Infections
Methicillin-Resistant Staphylococcus aureus
Catheters, Indwelling
Bacitracin
Carrier State
Microbial Sensitivity Tests
Anti-Infective Agents, Local
Nose
Peritonitis
Staphylococcus
Nasal Cavity
Emergence of mupirocin resistance in multiresistant Staphylococcus aureus clinical isolates belonging to Brazilian epidemic clone III::B:A. (1/232)
Mupirocin is a topical antimicrobial agent that has been successfully used to eradicate methicillin-resistant Staphylococcus aureus from the anterior nares and other sites of patients and health care personnel. This report describes the acquisition of a novel mupirocin resistance gene (ileS) by an epidemic MRSA clone that is geographically widespread in Brazil. (+info)Randomized, placebo-controlled, double-blind trial to evaluate the efficacy of mupirocin for eradicating carriage of methicillin-resistant Staphylococcus aureus. (2/232)
Mupirocin has been widely used for the clearance of nasal methicillin-resistant Staphylococcus aureus (MRSA) carriage during outbreaks, but no placebo-controlled trial has evaluated its value for eradicating MRSA carriage at multiple body sites in settings where MRSA is not epidemic. In a 1,500-bed teaching hospital with endemic MRSA, 102 patients colonized with MRSA were randomized into a double-blind, placebo-controlled trial and treated with either mupirocin (group M) or placebo (group P) applied to the anterior nares for 5 days; both groups used chlorhexidine soap for body washing. Follow-up screening, susceptibility testing, and genotyping were performed to evaluate treatment success, mupirocin or chlorhexidine resistance, and exogenous recolonization. At baseline, MRSA carriage was 60% in the nares, 38% in the groin, and 62% in other sites (skin lesions, urine). The MRSA eradication rate (all body sites) was 25% in group M (12 of 48 patients), compared to 18% in group P (9 of 50 patients; relative risk [RR], 0.72; 95% confidence interval [CI95], 0.33 to 1.55). At the end of follow-up, 44% of patients (19 of 43) were free of nasal MRSA in group M, compared to 23% (11 of 44) in group P (RR, 0.57; CI95, 0.31 to 1.04). Ten patients developed MRSA infections (three in group M and seven in group P). One mupirocin treatment failure was due to exogenous MRSA recolonization. No MRSA isolate showed chlorhexidine resistance or high-level mupirocin resistance; however, we observed an association (P = 0.003) between low-level mupirocin resistance at study entry (prevalence, 23%) and subsequent treatment failure in both study arms. These results suggest that nasal mupirocin is only marginally effective in the eradication of multisite MRSA carriage in a setting where MRSA is endemic. (+info)The antifungal activity of mupirocin. (3/232)
The antibacterial agent mupirocin (pseudomonic acid A) is used as a topical agent in the treatment of superficial infections by Gram-positive bacteria, particularly Staphylococcus aureus. However, we demonstrate here that the compound also inhibits the growth of a number of pathogenic fungi in vitro, including a range of dermatophytes and Pityrosporum spp. It inhibited the incorporation of amino acids and precursors of RNA, but not that of acetate, by Trichophyton mentagrophytes. It also inhibited the isoleucyl-tRNA synthetase from Candida albicans, indicating a mechanism of action similar to that in bacteria. When administered topically, mupirocin was efficacious in a T. mentagrophytes ringworm model in guinea pigs. These results suggest that mupirocin could have clinical utility for superficial infections caused by dermatophytes. (+info)Cost-effectiveness of prophylactic nasal mupirocin in patients undergoing peritoneal dialysis based on a randomized, placebo-controlled trial. (4/232)
The study objective was to measure the benefits of elimination of nasal carriage of Staphylococcus aureus by calcium mupirocin ointment in patients undergoing continuous ambulatory peritoneal dialysis. The design was a prospective, placebo-controlled, randomized clinical trial. The subjects were 267 patients recruited from nine renal units in Belgium, France and the UK. The main outcome measures were the rate of catheter exit site infection (ESI), rates of other infections and healthcare costs from the perspective of a hospital budget-holder. The rate of ESI caused by S. aureus was significantly reduced from one in 28.1 patient months to one in 99.3 patient months (P = 0.006) and there were also non-significant trends towards lower rates of ESI caused by any organism and peritonitis caused by S. aureus. In comparison with the placebo group, patients in the mupirocin group with ESI had lower antibiotic (P = 0.02) and hospitalization costs (P = 0.065). However, overall costs of antibiotic treatment, for all infections combined, were not significantly different (P = 0.2) and total antibiotic costs (including mupirocin) were significantly higher in the mupirocin group (P = 0.001). Mupirocin prophylaxis would have been cost-neutral if the rate of ESI increased to >75% in the placebo group, or if all healthcare costs increased by 40%, or if the cost of screening was reduced from Pound Sterling 15 to Pound Sterling 3 per patient, or if the cost of mupirocin treatment was reduced from Pound Sterling 93 to Pound Sterling 40 per patient year. In conclusion, savings in healthcare costs are unlikely to be sufficiently great to offset the cost of mupirocin and screening for nasal carriage of S. aureus. The decision about whether or not to implement mupirocin should depend on a local analysis of the value of preventing ESIs caused by S. aureus. (+info)A randomized clinical trial of mupirocin in the eradication of Staphylococcus aureus nasal carriage in human immunodeficiency virus disease. (5/232)
Seventy-six human immunodeficiency virus (HIV)-infected patients with Staphylococcus aureus nasal carriage were randomized to treatment groups receiving intranasal mupirocin or placebo twice daily for 5 days. Nasal cultures for S. aureus were obtained at 1, 2, 6, and 10 weeks after therapy. At 1 week, 88% of mupirocin-treated patients had negative nasal cultures compared with 8% in placebo patients (P<.001). The percentage of mupirocin-treated patients with persistently negative nasal cultures decreased over time (63%, 45%, and 29% at 2, 6, and 10 weeks, respectively) but remained significantly greater than the placebo group (3% at 2, 6, and 10 weeks). In mupirocin-treated patients, most (16/19) instances of nasal recolonization were with pretreatment strains (determined by means of by pulsed field gel electrophoresis); mupirocin resistance was not observed. Five days of treatment with mupirocin eliminated S. aureus nasal carriage in HIV-infected patients for several weeks; however, since the effect waned over time, intermittent dosing regimens should be considered for long-term eradication. (+info)Insights into editing from an ile-tRNA synthetase structure with tRNAile and mupirocin. (6/232)
Isoleucyl-transfer RNA (tRNA) synthetase (IleRS) joins Ile to tRNA(Ile) at its synthetic active site and hydrolyzes incorrectly acylated amino acids at its editing active site. The 2.2 angstrom resolution crystal structure of Staphylococcus aureus IleRS complexed with tRNA(Ile) and Mupirocin shows the acceptor strand of the tRNA(Ile) in the continuously stacked, A-form conformation with the 3' terminal nucleotide in the editing active site. To position the 3' terminus in the synthetic active site, the acceptor strand must adopt the hairpinned conformation seen in tRNA(Gln) complexed with its synthetase. The amino acid editing activity of the IleRS may result from the incorrect products shuttling between the synthetic and editing active sites, which is reminiscent of the editing mechanism of DNA polymerases. (+info)Outbreak of mupirocin-resistant staphylococci in a hospital in Warsaw, Poland, due to plasmid transmission and clonal spread of several strains. (7/232)
An outbreak of mupirocin-resistant (MuR) staphylococci was investigated in two wards of a large hospital in Warsaw, Poland. Fifty-three MuR isolates of Staphylococcus aureus, S. epidermidis, S. haemolyticus, S. xylosus, and S. capitis were identified over a 17-month survey which was carried out after introduction of the drug for the treatment of skin infections. The isolates were collected from patients with infections, environmental samples, and carriers; they constituted 19.5% of all staphylococcal isolates identified in the two wards during that time. Almost all the MuR isolates were also resistant to methicillin (methicillin-resistant S. aureus and methicillin-resistant coagulase-negative staphylococci). Seven of the outbreak isolates expressed a low-level-resistance phenotype (MuL), whereas the remaining majority of isolates were found to be highly resistant to mupirocin (MuH). The mupA gene, responsible for the MuH phenotype, has been assigned to three different polymorphic loci among the strains in the collection analyzed. The predominant polymorph, polymorph I (characterized by a mupA-containing EcoRI DNA fragment of about 16 kb), was located on a specific plasmid which was widely distributed among the entire staphylococcal population. All MuR S. aureus isolates were found to represent a single epidemic strain, which was clonally disseminated in both wards. The S. epidermidis population was much more diverse; however, at least four clusters of closely related isolates were identified, which suggested that some strains of this species were also clonally spread in the hospital environment. Six isolates of S. epidermidis were demonstrated to express the MuL and MuH resistance mechanisms simultaneously, and this is the first identification of such dual MuR phenotype-bearing strains. The outbreak was attributed to a high level and inappropriate use of mupirocin, and as a result the dermatological formulation of the drug has been removed from the hospital formulary. (+info)Efficacy of a new cream formulation of mupirocin: comparison with oral and topical agents in experimental skin infections. (8/232)
A new cream formulation of mupirocin developed to improve patient compliance was compared with systemic and topical antibiotics commonly used to treat primary and secondary skin infections. A mouse surgical wound model infected with Staphylococcus aureus or Streptococcus pyogenes was used. Topical treatment was applied at 4 and 10 h postinfection or oral treatment at a clinically relevant dose was administered 4, 8, and 12 h postinfection; treatments were continued three times daily for a further 3 days. Mupirocin cream was significantly more effective than (P < 0.01; two of eight studies) or not significantly different from (six of eight studies) mupirocin ointment in reducing bacterial numbers. Mupirocin cream was similar in efficacy to oral flucloxacillin but significantly more effective (P < 0.001) than oral erythromycin. It was also similar in efficacy to cephalexin against S. pyogenes but superior against S. aureus (P < 0.01). Mupirocin cream had a similar efficacy to fusidic acid cream against S. aureus but was significantly superior against S. pyogenes (P < 0.01). A hamster impetigo model infected with S. aureus was also used. Topical or oral treatment was administered at 24 and 30 h postinfection (also 36 h postinfection for oral therapy) and then three times daily for a further 2 days. On day 5, mupirocin cream was significantly more effective than mupirocin ointment in one study (P < 0.01) and of similar efficacy in the other two studies. Mupirocin cream was not significantly different from fusidic acid cream or neomycin-bacitracin cream, but it was significantly superior (P < 0.01) to oral erythromycin and cephalexin. Mupirocin cream was as effective as, or superior to, oral and other topical agents commonly used for skin infections. (+info)Staphylococcal infections can be classified into two categories:
1. Methicillin-Resistant Staphylococcus Aureus (MRSA) - This type of infection is resistant to many antibiotics and can cause severe skin infections, pneumonia, bloodstream infections and surgical site infections.
2. Methicillin-Sensitive Staphylococcus Aureus (MSSA) - This type of infection is not resistant to antibiotics and can cause milder skin infections, respiratory tract infections, sinusitis and food poisoning.
Staphylococcal infections are caused by the Staphylococcus bacteria which can enter the body through various means such as:
1. Skin cuts or open wounds
2. Respiratory tract infections
3. Contaminated food and water
4. Healthcare-associated infections
5. Surgical site infections
Symptoms of Staphylococcal infections may vary depending on the type of infection and severity, but they can include:
1. Skin redness and swelling
2. Increased pain or tenderness
3. Warmth or redness in the affected area
4. Pus or discharge
5. Fever and chills
6. Swollen lymph nodes
7. Shortness of breath
Diagnosis of Staphylococcal infections is based on physical examination, medical history, laboratory tests such as blood cultures, and imaging studies such as X-rays or CT scans.
Treatment of Staphylococcal infections depends on the type of infection and severity, but may include:
1. Antibiotics to fight the infection
2. Drainage of abscesses or pus collection
3. Wound care and debridement
4. Supportive care such as intravenous fluids, oxygen therapy, and pain management
5. Surgical intervention in severe cases.
Preventive measures for Staphylococcal infections include:
1. Good hand hygiene practices
2. Proper cleaning and disinfection of surfaces and equipment
3. Avoiding close contact with people who have Staphylococcal infections
4. Covering wounds and open sores
5. Proper sterilization and disinfection of medical equipment.
It is important to note that MRSA (methicillin-resistant Staphylococcus aureus) is a type of Staphylococcal infection that is resistant to many antibiotics, and can be difficult to treat. Therefore, early diagnosis and aggressive treatment are crucial to prevent complications and improve outcomes.
Some common types of staphylococcal skin infections include:
1. Boils: A boil is a red, swollen, and painful bump on the skin that is caused by an infection of a hair follicle or oil gland.
2. Abscesses: An abscess is a collection of pus that forms as a result of an infection. Staphylococcal abscesses can occur anywhere on the body and can be caused by a variety of factors, including cuts, burns, and insect bites.
3. Cellulitis: This is a bacterial infection of the skin and underlying tissues that can cause redness, swelling, and warmth in the affected area.
4. Furuncles: These are small, painful boils that occur under the skin, often on the face or neck.
5. Carbuncles: These are larger and more severe than furuncles, and can form in the armpits, groin, or other areas of the body.
6. Skin fold infections: These are infections that occur in skin folds, such as those found in obese individuals or those with skin conditions like eczema or dermatitis.
Staphylococcal skin infections can be caused by a variety of factors, including cuts, scrapes, insect bites, and contaminated tattoo or piercing equipment. They are typically treated with antibiotics, and in severe cases, may require surgical drainage of the infected area.
Preventive measures for staphylococcal skin infections include:
1. Practicing good hygiene, such as washing your hands regularly and thoroughly cleaning any cuts or scrapes.
2. Covering wounds with bandages to prevent germs from entering the body.
3. Avoiding sharing personal items, such as towels or razors, that may come into contact with infected skin.
4. Properly caring for and cleaning any tattoos or piercings.
5. Avoiding close contact with individuals who have staphylococcal infections.
6. Using mupirocin ointment or other antibiotic ointments to help prevent infection in individuals at high risk, such as those with skin conditions like eczema or dermatitis.
7. Using steroid-free topical products and avoiding the use of harsh soaps and cleansers that can strip the skin of its natural oils and make it more susceptible to infection.
8. Keeping wounds moist with antibiotic ointment and dressings to promote healing and prevent infection.
The symptoms of peritonitis can vary depending on the severity and location of the inflammation, but they may include:
* Abdominal pain and tenderness
* Fever
* Nausea and vomiting
* Diarrhea or constipation
* Loss of appetite
* Fatigue
* Weakness
* Low blood pressure
Peritonitis can be diagnosed through a physical examination, medical history, and diagnostic tests such as a CT scan, MRI or ultrasound. Treatment usually involves antibiotics to clear the infection and supportive care to manage symptoms. In severe cases, surgery may be required to remove any infected tissue or repair damaged organs.
Prompt medical attention is essential for effective treatment and prevention of complications such as sepsis, organ failure, and death.
Mupirocin
GSK plc
Decolonization (medicine)
Impetigo
Staphylococcus aureus
Bullous impetigo
Pitted keratolysis
Methicillin-resistant Staphylococcus aureus
Paronychia
FPG IleRS zinc finger
Pyoderma gangrenosum
Folliculitis
Peritoneal dialysis
Angular cheilitis
Pseudomonas fluorescens
Rifalazil
Skin flora
Acne
Transmission-based precautions
Perianal cellulitis
Didier Pittet
Curacin A
Staphylococcus pseudintermedius
Microbial ecology
List of antibiotics
ATC code D06
Mometasone
ATC code R01
WHO Model List of Essential Medicines
WHO Model List of Essential Medicines for Children
MUPIROCIN
Mupirocin: MedlinePlus Drug Information
MedlinePlus - Search Results for: mupirocin
Mupirocin Ointment | 1800PetMeds
Mupirocin - PubMed
Mupirocin - PubMed
Mupirocin - Drugs and Lactation Database (LactMed®) - NCBI Bookshelf
Mupirocin (Bactroban) Prices - U.S. & International | PharmacyChecker.com
MUPIROCIN
Staphylococcus Aureus Infection Medication: Antistaphylococcal Antibiotics, Cephalosporins, Blood Products
BACTROBAN (Mupirocin) - Medgeneric
Is mupirocin for burns helpful?
Effective decolonization strategy for mupirocin-resistant |i|Staphylococcus aureus|/i| by TPGS-modified mupirocin-silver...
MUPIROCIN OINT USP 2% (BACTROBAN) 22GM
Order discount Mupirocin Australia, Does - Get Lost
MUPIROCIN...2.0% W/W (CREAM BASE) | Lifevisionindia
B-Bact Ointment 10gm | Mupirocin | 20% OFF | Medic Scales
DailyMed - Search Results for RNA Synthetase Inhibitors
NDC 68788-8941 Topical Ointment Mupirocin Drug Codes, Packaging, Active Ingredients
Table 4 - Methicillin-resistant Staphylococcus aureus, Western Australia - Volume 11, Number 10-October 2005 - Emerging...
Impetigo national library of medicine, over the counter mupirocin tablets - Beter HBO
Topic: Achetez Mupirocin en ligne sans ordonnance, Mupirocin for bug | Team nais0ne.com
General ENT Clinic | Otolaryngology - Head & Neck Surgery | Stanford Medicine
7 Leading Cost Savings Tips to know about Mupirocin Ointment for Boils - Best Rx For Savings
Journal Watch - Home Dialysis Central
RFA-CI-06-003: Antimicrobial Resistance
Specialized Medications Used Against Bacteria: Bacitracin, Mupirocin, Clindamycin, Metronidazole & Tinidazole, Vancomycin,...
Ointment6
- Mupirocin comes in an ointment that is applied to the skin. (medlineplus.gov)
- Do not let mupirocin ointment get into your eyes, nose, or mouth, and do not swallow it. (medlineplus.gov)
- A separate formulation, mupirocin nasal ointment, is available for intranasal use. (nih.gov)
- As such, a prescription ointment with Bactroban (mupirocin) may be necessary. (allegromedical.com)
- Ointments such as silver sulfadiazine and 2% mupirocin ointment are available for treating localized bacterial infections. (aaep.org)
- This patient was treated with mupirocin ointment, applied 4 times daily. (contemporarypediatrics.com)
Antibiotic4
- Mupirocin, an antibiotic, is used to treat impetigo as well as other skin infections caused by bacteria. (medlineplus.gov)
- Mupirocin is a type of antibiotic. (lifevisionindia.com)
- Mupirocin (formerly pseudomonic acid) is a naturally occurring antibiotic produced by Pseudomonas fluorescens active against most gram-positive cocci, including methicillin-sensitive and methicillin-resistant S aureus and most streptococci (but not enterococci). (mhmedical.com)
- The trial evaluated whether daily bathing with the antiseptic soap chlorhexidine (CHG) - and in those patients with methicillin-resistant Staphylococcus aureus (MRSA), adding the nasal antibiotic mupirocin - more effectively reduced hospital-acquired bacterial infections than bathing with ordinary soap and water. (nih.gov)
Topical3
- Topical mupirocin, fusidic acid, and nadifloxacin are used in the treatment of superficial bacterial infections. (ijdd.in)
- and the topical antibiotics mupirocin (launched 1985), a pseudomonic acid, and retapamulin ( 3 ), a pleuromutilin derivative. (nature.com)
- 7. Development of microsponges for topical delivery of mupirocin. (nih.gov)
Bacterial Infections2
- To compare the efficacy and safety profile of 2% mupirocin versus 2% fusidic acid versus 1% nadifloxacin cream in the treatment of superficial bacterial infections. (ijdd.in)
- This study documents the equality in the comparative safety and efficacy of mupirocin, fusidic acid, and nadifloxacin in the treatment of uncomplicated superficial bacterial infections at our center. (ijdd.in)
Retapamulin1
- For this portion of the study, all cultures will additionally undergo disk susceptibility testing for retapamulin, erythromycin, clindamycin (including D-test), trimethoprim sulfa, and mupirocin (5 mcg and 20 mcg disks). (drugpatentwatch.com)
Aureus5
- High rates of mupirocin resistance have been observed in methicillin-resistant S aureus isolates from surgical intensive care unit patients, despite minimal in-hospital mupirocin use. (mhmedical.com)
- The IDSA recommends the use of mupirocin with chlorhexidine preferentially over oral antibacterials for methicillin-resistant S aureus decolonization. (mhmedical.com)
- Lower percentages of resistant strains of Staphylococcus aureus to mupirocin (11.88%) and ciprofloxacin (0.99%) were observed. (who.int)
- Staphylococcus aureus , mupirocin susceptibility. (who.int)
- Multidrug and Mupirocin Resistance in Environmental Methicillin-Resistant Staphylococcus aureus (MRSA) Isolates from Homes of People Diagnosed with Community-Onset MRSA Infection. (nih.gov)
MRSA2
- If I am on a decolonizing MRSA regime using mupirocin in my nose, armpits, and groin folds should I not partake in sexual intercourse? (healthtap.com)
- During a trial of patients with CO-MRSA infection, MRSA was isolated from the household environment at the baseline and 3 months later, following randomization of patients and household members to mupirocin-based decolonization therapy or an education control group. (nih.gov)
Resistance1
- However, recurrent colonization occurs (50% at the end of 1 year), and when mupirocin is used long-term over months, resistance can emerge. (mhmedical.com)
Nasal1
- Mupirocin / Lidocaine Nasal Spray, Mupirocin Nasal Spray. (collegepharmacy.com)
Gauze1
- Apply a small amount of mupirocin cream, with a cotton swab or gauze pad, to the affected area 3 times daily for 10 days. (nih.gov)
Impetigo1
- Mupirocin is equal to oral beta-lactams in the treatment of mild impetigo. (mhmedical.com)
Drugs1
- tell your doctor and pharmacist if you are allergic to mupirocin or any other drugs. (medlineplus.gov)
Cream8
- These highlights do not include all the information needed to use MUPIROCIN CREAM safely and effectively. (nih.gov)
- See full prescribing information for MUPIROCIN CREAM. (nih.gov)
- Cream: 20 mg (2% w/w) of mupirocin per gram in 15-gram and 30-gram tubes. (nih.gov)
- Known hypersensitivity to mupirocin or any of the excipients of mupirocin cream. (nih.gov)
- Severe Allergic Reactions: Anaphylaxis, urticaria, angioedema, and generalized rash have been reported in patients treated with formulations of mupirocin, including mupirocin cream. (nih.gov)
- Risk Associated with Mucosal Use: Mupirocin cream is not formulated for use on mucosal surfaces. (nih.gov)
- Mupirocin cream USP is a white cream that contains 20 mg (2% w/w) of mupirocin per gram in an oil- and water-based emulsion, supplied in 15-gram and 30-gram tubes. (nih.gov)
- In the event of a sensitization or severe local irritation from mupirocin cream, usage should be discontinued, and appropriate alternative therapy for the infection instituted. (nih.gov)
Patients3
- Studies demonstrate an associated reduction in postoperative staphylococcal lung infections in colonized patients treated with mupirocin . (mhmedical.com)
- While no statistically significant difference between the two intervention groups was seen within the population overall, the researchers did find that one subset of patients - those with medical devices - experienced a substantial benefit if they received the CHG/mupirocin intervention. (nih.gov)
- However, patients with medical devices, such as central venous catheters or lumbar drains, benefitted from the CHG/mupirocin intervention. (nih.gov)
Apply2
- Do not apply mupirocin to your eyes. (medlineplus.gov)
- Do not apply mupirocin to burns unless told to do so by your doctor. (medlineplus.gov)
Side effects2
- Mupirocin may cause side effects. (medlineplus.gov)
- Mupirocin should not be stopped because of these minor side effects. (lifevisionindia.com)
Common1
- A burning sensation is a common side effect of Mupirocin use. (lifevisionindia.com)
Benefit1
- This finding suggests the benefit of mupirocin is limited . (mhmedical.com)
Require1
- mupirocin Reducing the temperature is approached the experiments generally require more time. (goldgreiner.de)